12:00 AM
 | 
May 11, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GENZ-644470: Phase II/III started

Genzyme disclosed that in March it began the double-blind, U.S. Phase II/III LEAP trial to compare 3 dosages of GENZ-644470 vs. 3 dosages of...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >